Across TCGA pan-cancer cohorts, TRAJ22 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated TRAJ22 data layer.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher TRAJ22 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAJ22 expression acts as an unfavorable survival marker, although some lineages such as DLBC and SKCM show a favorable association.
GBM, BLCA, and HNSC are the cancer types where TRAJ22 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.